Please use this identifier to cite or link to this item:
|Title:||Central composite designed ezetimibe solid dispersion for dissolution enhancement: Synthesis and in vitro evaluation|
polyvinyl pyrollidone K30
solvent evaporation technique
|Publisher:||Future Medicine Ltd.|
|Abstract:||Aim: The current research is focused on increasing aqueous solubility and dissolution of BCS class II drug by using modified solvent evaporation technique to produce solid dispersions of ezetimibe (EZSD) using gelucire 50/13 and polyvinyl pyrollidone K30. Methodology & results: Central composite design analyzed the effect of gelucire 50/13 and polyvinyl pyrollidone K30 on the percentage of drug released in 5 and 30 min. Ezetimibe (EZ) aqueous saturation solubility (4.56 � 0.94 ?g/ml) was increased 25-fold in EZSD (115 � 3.41 ?g/ml). Cumulative drug release from EZ and optimized EZSD were observed 24.67 and 87.54% within 1 h, respectively. Conclusion: Manufacturing EZSD using modified solvent evaporation technique using rotary evaporator holds great promise for enhancing EZ's solubility and dissolution.|
|Appears in Collections:||Journals|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.